Details of the Drug

General Information of Drug (ID: DMHKJ5I)

• Drug Name: Nabiximols
• Synonyms: Nabiximols; Sativex; GW-1000; Cannador; Nabiximols [USAN]; GW1000; GW 1000; Tetrahydrocannabinol-cannabidiol combination; Cannabidiol mixture with Tetrahydrocannabinol; delta-9-Tetrahydrocannabinol and cannabidiol; Cannabidiol and delta-9-tetrahydrocarnabinol; GW-1000-02

Indication

Disease Entry	ICD 11	Status	REF
Cancer related pain	MG30	Phase 3	[1]
Muscle spasm	MB47.3	Phase 3	[2]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight; 628.9
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 10
  Hydrogen Bond Donor Count; 3
  Hydrogen Bond Acceptor Count; 4
• ADMET Property:
  Half-life: The concentration or amount of drug in body reduced by one-half in 24 - 36 hours [3]
  Metabolism: The drug is metabolized via the liver []
• Chemical Identifiers:
  Formula: C42H60O4
  IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
  Canonical SMILES: CCCCCC1=CC(=C(C(=C1)O)C2C=C(CC[C@H]2C(=C)C)C)O.CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O
  InChI: InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18?/m10/s1
  InChIKey: SSNHGLKFJISNTR-FWUPRJFYSA-N
• Cross-matching ID:
  PubChem CID: 44148067
  CAS Number: 56575-23-6
  UNII: K4H93P747O
  DrugBank ID: DB14011
  TTD ID: D0C5CE
  INTEDE ID: DR1121
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[5]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[6]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Actin, cytoplasmic 1 (ACTB)	OT1MCP2F	ACTB_HUMAN	Gene/Protein Processing	[7]
E3 ubiquitin-protein ligase DTX3L (DTX3L)	OTCCO2QZ	DTX3L_HUMAN	Gene/Protein Processing	[7]
Fructose-bisphosphate aldolase A (ALDOA)	OTWRFTIB	ALDOA_HUMAN	Gene/Protein Processing	[7]
Guanylate-binding protein 5 (GBP5)	OTS4AO4A	GBP5_HUMAN	Gene/Protein Processing	[7]
Histone H4 (H4C1)	OTB71W46	H4_HUMAN	Gene/Protein Processing	[7]
Large ribosomal subunit protein uL6 (RPL9)	OTKE01O8	RL9_HUMAN	Gene/Protein Processing	[7]
Lymphocyte-specific protein 1 (LSP1)	OTSPSIFO	LSP1_HUMAN	Gene/Protein Processing	[7]
Neurogranin (NRGN)	OTVGE10W	NEUG_HUMAN	Gene/Protein Processing	[7]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Gene/Protein Processing	[7]
POTE ankyrin domain family member F (POTEF)	OTV3WXYE	POTEF_HUMAN	Gene/Protein Processing	[7]

References

• [1] Clinical pipeline report, company report or official report of GW Pharmaceuticals.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1219-28.
• [5] Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
• [6] Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
• [7] Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16.